Virus-specific T-cell therapy in solid organ transplantation

Abstract

This article reviews the current state of T-cell therapy as therapeutic option for virus-associated diseases against the background of the most common viral complications and their standard treatment regimens after SOT. The available data of clinical T-cell trials in SOT are summarized. References to the hematopoietic stem cell transplantation are made if applicable data in SOT are not available and their content was considered likewise valid for cell therapy in SOT. Moreover, aspects of different manufacturing approaches including beneficial product characteristics and the importance of GMP compliance are addressed.

Keywords: Epstein-Barr virus; T-cell therapy; good manufacturing practices; human cytomegalovirus; solid organ transplantation; virus-specific.